CervoMed Inc CRVO Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.42 down $0.03, 2.07% at close Nov 6
Last close · Previous close $1.45
- Market cap
- $13.15MAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$3.22Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$1.42down $0.03, 2.07%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.45Nov 5
- Volume587.08KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume346.69KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.27 to $10.00; now $1.42
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CRVO trailed the S&P 500 in all 7 periods.
| Period | CRVO and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CRVO: down 57.5% S&P 500: down 5.6% | CRVO trailed the S&P 500 by 51.9 percentage points Trailed |
| 3M | CRVO: down 48.6% S&P 500: down 4.1% | CRVO trailed the S&P 500 by 44.5 percentage points Trailed |
| YTD | CRVO: down 82.0% S&P 500: up 8.7% | CRVO trailed the S&P 500 by 90.7 percentage points Trailed |
| 1Y | CRVO: down 80.5% S&P 500: up 10.9% | CRVO trailed the S&P 500 by 91.4 percentage points Trailed |
| Long term | ||
| 3Y | CRVO: down 87.1% S&P 500: up 75.0% −49.5% vs +20.5% a year | CRVO trailed the S&P 500 by 162.1 percentage points Trailed |
| 5Y | CRVO: down 95.8% S&P 500: up 67.8% −47.0% vs +10.9% a year | CRVO trailed the S&P 500 by 163.6 percentage points Trailed |
| 10Y | CRVO: down 100.0% S&P 500: up 305.4% −55.4% vs +15.0% a year | CRVO trailed the S&P 500 by 405.4 percentage points Trailed |
$10,000 invested in CRVO 10 years ago (Oct 31, 2016) would be worth about $3 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $40,535.
CRVO trailed the S&P 500 in all 7 periods.
| Period | CRVO and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CRVO: down 57.5% S&P 500: down 5.6% | CRVO trailed the S&P 500 by 51.9 percentage points Trailed |
| 3M | CRVO: down 48.6% S&P 500: down 4.3% | CRVO trailed the S&P 500 by 44.3 percentage points Trailed |
| YTD | CRVO: down 82.0% S&P 500: up 7.8% | CRVO trailed the S&P 500 by 89.8 percentage points Trailed |
| 1Y | CRVO: down 80.5% S&P 500: up 9.7% | CRVO trailed the S&P 500 by 90.2 percentage points Trailed |
| Long term | ||
| 3Y | CRVO: down 87.1% S&P 500: up 68.8% −49.5% vs +19.1% a year | CRVO trailed the S&P 500 by 155.9 percentage points Trailed |
| 5Y | CRVO: down 95.8% S&P 500: up 56.9% −47.0% vs +9.4% a year | CRVO trailed the S&P 500 by 152.7 percentage points Trailed |
| 10Y | CRVO: down 100.0% S&P 500: up 245.9% −55.4% vs +13.2% a year | CRVO trailed the S&P 500 by 345.9 percentage points Trailed |
$10,000 invested in CRVO 10 years ago (Oct 31, 2016) would be worth about $3 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $34,594.
All-time high
$19,125.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Jan 4, 2016.
Stock splits
4
Latest: 2-for-3 on . Share counts adjust after each split.
All 4 splits
- 2-for-3
- 1-for-50
- 1-for-15
- 1-for-10
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$3.22 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 39.7×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 0.6×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −212.80%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - −$11.79MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own CRVO DCF in Excel. Value CervoMed with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $331.30Kdown 95.7%
- Net income
- −$30.35M
- Diluted EPS
- −$3.22
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $1.94M | −$4.75M | −$0.55 |
| Q4 FY24 (Dec 31, 2024) | $2.16M | −$6.71M | −$0.80 |
| Q1 FY25 (Mar 31, 2025) | $1.92M | −$4.89M | −$0.56 |
| Q2 FY25 (Jun 30, 2025) | $1.76M | −$6.26M | −$0.70 |
| Q3 FY25 (Sep 30, 2025) | $322.57K | −$7.73M | −$0.84 |
| Q4 FY25 (Dec 31, 2025) | $8.73K | −$8.09M | −$0.88 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$7.96M | −$0.86 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$6.57M | −$0.64 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$24.10M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$5.80M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $7.14M | −$2.17M | −$0.82 |
| FY24 (Dec 31, 2024) | $9.74M | −$16.29M | −$2.02 |
| FY25 (Dec 31, 2025) | $4.01M | −$26.97M | −$2.98 |
Margins
- Gross 100.0%
- Operating −9,407.0%
- Net −9,160.9%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$27.98MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$27.98MLast 12 months
- Capital spending$0.00Last 12 months
- −8,444.9%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $18.93MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $24.94MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$0.00As of Jun 30, 2026
- Net cash$24.94MAs of Jun 30, 2026
- 8.57As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 3 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −156.0%Last 12 months
Over the last 12 months, CervoMed lost money: its net loss was 156.0% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −128.3%Last 12 months
Over the last 12 months, CervoMed’s net loss was 128.3% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About CervoMed Inc
Diffusion Pharmaceuticals Inc. is a biopharmaceutical company that has historically focused on developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most. Diffusion’s most advanced product candidate, trans sodium crocetinate (TSC), has been investigated and developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, most recently as an adjuvant treatment to standard of care therapy for GBM and other hypoxic solid tumors. In connection with the proposed merger with EIP, and pending its conclusion, Diffusion previously paused the initiation of the previously announced Phase 2 study of TSC in newly diagnosed GBM patients and will continue to attempt to identify sale or out-licensing transactions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Virginia, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CRVO news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CRVO stock FAQ
What is CRVO stock’s price today?
CervoMed (CRVO) traded at $1.42 at the close on , down $0.03 (2.07%) from the previous close of $1.45. Over the past 52 weeks it has traded between $1.27 and $10.00.
If you invested $1,000 in CRVO 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CRVO on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $42 if invested five years ago and $195 if invested one year ago. Past performance doesn’t predict future returns.
What is CervoMed’s market cap?
CervoMed’s market capitalization is about $13.1 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $1.42 (how market cap works). CervoMed reported 9.26M shares outstanding at the end of its latest quarter ().
What is CRVO’s P/E ratio?
CRVO’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$3.22).
How much revenue does CervoMed make?
CervoMed reported $331.3 thousand of revenue over the four quarters to , down 95.7% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $0.0 thousand, down 100.0% from a year earlier.
Is CervoMed profitable?
Not over the four quarters to . CervoMed reported a net loss of $30.3 million across those four quarters on $331.3 thousand of revenue.
What are CRVO’s earnings per share?
CRVO’s diluted earnings per share were −$3.22 over the four quarters to , compared with −$2.61 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.64 per share, against −$0.70 a year earlier (how EPS works).
Does CRVO pay a dividend?
CervoMed hasn’t paid a dividend in the last twelve months.
What is CRVO’s 52-week high and low?
Over the past 52 weeks CRVO has traded as low as $1.27 and as high as $10.00. At $1.42 at the close on , it is 85.8% below that high and 11.8% above the low.
What is CRVO’s all-time high?
CRVO’s highest closing price was $19,125.00 on , adjusted for stock splits. At $1.42 at the close on , it is 100.0% below that record.
Has CRVO stock ever split?
Yes, four times: 1-for-10 on ; 1-for-15 on ; 1-for-50 on ; 2-for-3 on .
How has CRVO stock performed?
Including dividends and measured to the close on , CRVO has returned −82.0% so far this year and −80.5% over the past year, and −95.8% over five years (−47.0% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is CervoMed in?
CervoMed is in the Healthcare sector and the Biotechnology industry, and is headquartered in Virginia, USA.
What exchange does CRVO trade on?
CervoMed trades on the Nasdaq under the ticker symbol CRVO. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.